Search
Appellate Practice And Procedure: Meet The New Court Of Appeals Judge - A Conversation With Judge Ede Governor Walz appointed Judge Ede to the Minnesota Court of Appeals in July. Prior to joining the appellate court, he served as a District Court Judge in Hennepin County. Judge Ede has had a...
Certain immigrant investors using the EB-5 Program will not be restricted by Florida S.B. 264, creating restrictions on certain nationals owning direct or indirect real estate in the State of Florida.
Panel 4: The Connections Between Insurance and Litigation Funding Join Partner Brian Michalek and the University of Chicago Center on Law and Finance , in sponsorship with Burford Capital and Alliant, at the 2023 Chicago Conference on Litigation Finance. This conference will explore the policy...
Have you dreamed of living in a different country? Explore new investment opportunities? Join Cynthia Gomez in Medellín and Bogotá on October 3 and 4 for an exciting event about investing and residing in the United States and Spain.
Saul Ewing’s Casey Grabenstein and Andrew Schwerin write that courts are divided on whether plaintiff bias justifies discovery about litigation funding. They argue litigation funding wouldn’t often create a conflict of interest for a plaintiff.
EB-5 Visa 2.0: Current Trends in the Program Interest in the EB-5 program, especially among individuals in the U.S. on H-1B and F-1 visas who intend to concurrently file an EB-5 visa, is at an all-time high. While the opportunity to obtain a green card through investment was reauthorized by Congress...
Contingent Liability Insurance Demystified Partner Brian Michalek will speak on a panel during the 2023 Transaction Solutions Symposium. More information to come.
Appellate Practice: Celebrating 40 years at the Minnesota Court of Appeals Katie Barrett Wiik and co-panelist Jon Schmidt will discuss the rich history at the Minnesota Court of Appeals with the current Chief Judge and several former Chief Judges. - Jon Schmidt; Assistant Hennepin County Attorney –...
On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...